# Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Canonical URL: https://biopharmsignal.com/news/CLRB/cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer-tnbc
Ticker: CLRB
Company: Cellectar Biosciences
Source: Cellectar Biosciences
Published: 2026-04-14 12:35 EST
Original Source URL: https://www.cellectar.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-15 11:30 EST — [Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-publication-of-phase-1-study-of-iopofosine-i-131-1d5d4326) — Source: Cellectar Biosciences
- 2026-06-01 12:05 EST — [Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-highlight-compelling-new-efficacy-data-from-phase-2b-clover-wam-study-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia-at-the-american-society-of-clinical-oncology-annual-meeting) — Source: Cellectar Biosciences
- 2026-05-14 11:15 EST — [Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updates) — Source: Cellectar Biosciences
- 2026-05-11 12:05 EST — [Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-a-conference-call-on-thursday-may-14-2026) — Source: Cellectar Biosciences
- 2026-05-05 11:10 EST — [Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia) — Source: Cellectar Biosciences
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)